Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Cardiff Oncology, Inc. (CRDF) is a Biotechnology company based in US with a market capitalization of $57.4M. Revenue declined 13.2% year-over-year and free cash flow was negative at -$38M. This page tracks CRDF's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 32 employees · IPO Jul 27, 2004
Valuation
Valuation & price
$1.67as of May 17, 2026· -57.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.27
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$57.4M
Market cap
-13.2%
Revenue growth (YoY)
100.0%
Gross margin
-$38M
Free cash flow (USD)
-$57.5M
Net debt
Net cash position
40.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
4
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-0.18)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 16, 2026Filing
Insider Buy $50KMohindru Mani · Director, Chief Executive Officer · $50K
- Insider buyJul 16, 2026Filing
Insider Buy $1000KPACE GARY W · Director · $1M
- 8-K eventJul 16, 2026Filing
Securities Purchase Agreement
- Insider buyJun 22, 2026Filing
Insider Buy $37KPACE GARY W · Director · $36.6K
- Insider buyJun 22, 2026Filing
Insider Buy $30KMohindru Mani · Director, Chief Executive Officer · $29.9K
- 8-K eventJun 11, 2026Filing
Annual Meeting Results
- 8-K eventJun 3, 2026Filing
Investor Presentation
- 8-K eventMay 29, 2026Filing
License Agreement Termination
- 8-K eventMay 19, 2026Filing
Lawsuit Filed
- Quarterly reportMay 14, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Cardiff Oncology, Inc.'s market cap?
Cardiff Oncology, Inc. (CRDF) has a market capitalization of $57.4M.
What is CRDF's P/E ratio?
A meaningful P/E ratio is not available for CRDF — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CRDF's price-to-book (P/B) ratio?
CRDF trades at 1.27 times book value per share.
When did Cardiff Oncology, Inc. last report earnings?
CRDF last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying CRDF stock?
Yes — SEC Form 4 filings show 4 open-market insider buys and 0 sells at Cardiff Oncology, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.